Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Draft ‘Cures’ Bill Allows Advance Accelerated Approval Agreements

This article was originally published in The Pink Sheet Daily

Executive Summary

Latest iteration of House’s 21st Century Cures legislation drops brand exclusivity extensions that had been floated previously.

You may also be interested in...



Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start

Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?

Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start

Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?

Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining

HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.

Related Content

Topics

UsernamePublicRestriction

Register

PS078426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel